Alberto Batticciotto

Learn More
The immunogenicity of anti-TNF-α drugs may affect their safety and efficacy. Infliximab (IFX), a chimeric monoclonal antibody, induces antibody formation in up to 60 % of cases. Some studies have suggested the involvement of a Th1 response to TNFα blockers following immunization, but the triggering of Th17 responses has never been reported. The aim of this(More)
INTRODUCTION Only limited information is available on cost efficacy of the various biological agents used to treat patients with rheumatoid arthritis with intolerance or for whom it would be inappropriate to continue treatment with conventional agents. We estimated the efficacy and treatment costs of monotherapy with biological agents in the treatment of(More)
Erratum After publication of the original article [1], it came to the authors' attention that there were spelling errors in the surnames of two of the authors. The surnames of A. Batticciotto and A. Draghessi were misspelled but appear correctly in this erratum. et al. Hidden musculoskeletal involvement in inflammatory bowel disease: a multicenter(More)
  • 1